|
 BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, today announced its selection of Ken Malone, Ph.D., of Early Charm Ventures, as the first BHI Entrepreneur-in-Residence (EIR) assigned to work directly with UM Ventures. Dr. Malone, a serial entrepreneur who has founded or been an officer of five biotechnology or advanced materials companies, will help advance the commercialization efforts of new start-up companies based upon innovative discoveries coming out of research programs at the University of Maryland (UMD) College Park and Baltimore.
“We’re thrilled to name Ken Malone as an EIR,” said Richard Bendis, BHI President & CEO. “Ken and I have a long history of working together, so I know first hand that he has the experience, drive and perspective to be a true asset to BHI and to the many start-ups he’ll serve from University of Maryland in support of the newly launched UM Ventures initiative.” Dr. Malone will assist any interested UM start-ups once they have been launched.
back to top 
Date: Wednesday, May 8th, 2013 9:30am-5:00pm
Location: Morgan, Lewis & Bockius Conference Center, 1111 Pennsylvania Ave., NW Washington, DC 20004-2541
National Brain Tumor Society is bringing together brain tumor researchers and industry executives to discuss how to move research from bench to bedside.
- Biophrama executives and VC investors will share their criteria for investment and licensing of academic research.
- Panelists include:
- Lauren Abrey
Global Development Team Lead, Genetech/Roche
- Neil Exter
Partner, Third Rock
- Brian Gallagher
Partner, SROne
- Michael Glutch
Managing Director, Medimmune Ventures
- Perry Nisen
Senior VP of Science Transactions, Pfizer
- Nation Brain Tumor Society-funded researchers will present brain tumor drug candidates ready for early stage investment and/or licensing.
back to top
Time-reversal techniques for optimizing broadband communication networks and rapid prototyping of microfluidics devices were among the Clark School of Engineering inventions recognized as the most promising new technologies at the University of Maryland Invention of the Year Awards.
The University of Maryland’s Office of Technology Commercialization (OTC) hosted the 26th Annual Invention of the Year Awards reception on Tuesday, April 16, 2013 from 4:30-6:00 pm at the University of Maryland Golf Course Club House.
back to top
The Biotechnology Industry Organization (BIO) is pleased to announce the election of Rachel King, President and CEO, GlycoMimetics, Inc, as the new Chair of its Board of Directors for the 2013-2014 term, and the election of David Pyott, Chairman, President, & CEO, Allergan, Inc., as its new Board Secretary. BIO also is pleased to announce the re-election of Mark Skaletsky, Chairman & CEO, Fenway Pharmaceuticals, Inc., as Board Treasurer, and the election of 19 Directors to serve on BIO's Board Executive Committee for the new term. In addition, BIO welcomes the election of eight new members to its Board of Directors, voted upon at this year's 2013 BIO International Convention.
"Rachel King brings a depth of industry experience and passion for advocacy that will serve BIO and its members well," said Jim Greenwood, BIO President & CEO. "I look forward to working closely with Rachel and our newly-constituted Board of Directors in the years to come."
back to top
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an asset purchase agreement to acquire the Healthcare Protective Products Division (HPPD) of Bracco Diagnostics Inc. in an all-cash transaction that includes payment of $26.0 million upon closing. The acquisition will diversify and expand Emergent’s biodefense franchise by adding product sales from HPPD’s marketed chemical countermeasure, RSDL (Reactive Skin Decontamination Lotion). The acquisition offers Emergent an opportunity to leverage its core capabilities in manufacturing, government contracting, government sales, and product distribution as it looks to substantially expand sales of RSDL in the attractive and growing chemical countermeasure market.
“This acquisition directly supports our ongoing growth plan, which includes acquiring revenue generating, profitable products and businesses that address the needs of U.S. and allied foreign governments across the CBRN spectrum,” stated Daniel J. Abdun-Nabi, president and chief executive officer of Emergent BioSolutions. “Our relationships, combined with those of HPPD, with the U.S. Government and foreign ministries of defense, as well as worldwide distributor relationships addressing first responder markets, should enable us to grow revenues from RSDL and to expand and enhance Emergent’s leadership position as a premier supplier of CBRN countermeasures.”
back to top
Last year AstraZeneca's ($AZN) MedImmune did about 20 biologics deals, not counting the academic pacts it assembled. This year, MedImmune R&D chief Bahija Jallal tells me, there will be no letup in talent scouting. "If we do as little or more than last year," says Jallal, "I would be happy."
Echoing late-stage R&D chief Briggs Morrison--who spoke with me at BIO last week--Jallal singled out cardiovascular/metabolics, respiratory and cancer as key fields for new deals. She noted particular interest in brown fat, a focus for weight-loss fans, and immunotherapeutics, which has emerged as one of the hottest sectors in oncology R&D.
back to top
ETC, Baltimore City’s technology innovation center, announced today that it has chosen a new Baltimore City location to house it’s award winning technology incubator when its current Canton lease expires in October 2013. The ETC will move to 101 N. Haven Street, an adaptive reuse of an historic industrial building that was once home to the King Cork and Seal Company. The recently renovated building is located near Highlandtown with easy access to I-95 and is within the Enterprise Zone and a HUBZone. The ETC will maintain space in its other location at Johns Hopkins University - Eastern Campus on 33rd Street.
“The Emerging Technology Center has championed small business development and job creation in Baltimore for years, and we are proud to have supported their efforts,” said Baltimore Mayor Stephanie Rawlings-Blake. “We wish them the best of luck and success in their new location. I’m confident that the ETC will continue to be an important driver of innovation and entrepreneurship in the city. ”
back to top
Maryland often has been at the forefront of innovation with a longstanding reputation for investing in science and technology to capture new opportunities for economic growth. This year's legislative session was no different. Lawmakers backed Gov. Martin O'Malley's proposals to support the state's bioscience sector, expand the R&D tax credit, enhance workforce training, and promote measures to establish the state as a leader in cybersecurity.
back to top
I wanted to share some data with you that illustrates the strength of Montgomery County's business community: total employment in the County grew by nearly 25,000 jobs - from 631,000 jobs in 2010 to 655,800 jobs in 2012! This is impressive given the economic climate and shows the resiliency and fortitude of our local businesses - large and small.
The top job gaining sector was professional, scientific and technical services, which added almost 5,300 jobs beteen 2010 and 2012. The other top growing sectors were government, retail trade and health care and social assistance, each adding over 3,000 jobs during the three year period.
back to top
MedImmune has acquired Ann Arbor-based AlphaCore Pharma, creating another exit for a local up-and-coming start-up.
MedImmune, the global biologics research and development arm of AstraZeneca, has not disclosed the acquisition price nor its intentions on whether to keep the start-up in Tree Town. Tracy Rossin, director of corporate public relations for MedImmune, did write in an email that the company does "not have plans to expand its operations/workforce in Ann Arbor." She does add that her firm is "planning to incorporate AlphaCore Pharma into the larger AstraZeneca organization."
back to top
What if you could create a biotech startup focused on treating a rare disease, with a drug candidate already in hand, and high odds of success in clinical trials?
That’s the concept that crystallized in former MedImmune executive David Mott’s mind through decades of experience in the life sciences sector. The idea ultimately led him to start a Cambridge, MA-based biotech incubator called Cydan. This new organization, formally announced this month, has been staffed with a hand-picked squad of specialists tasked with churning out a lineup of small companies that make drugs for orphan diseases.
back to top
The purpose of the NHLBI SBIR Phase IIB Bridge Award is to facilitate and accelerate the capital-intensive steps that are required to transition SBIR Phase II projects to the commercialization stage by promoting partnerships between SBIR Phase II awardees and third-party investors and/or strategic partners. The Bridge Award encourages business relationships between applicant small business concerns and third-party investors/strategic partners who can provide substantial financing to help accelerate the commercialization of promising new products and technologies that were initiated with SBIR funding. In particular, applicants are expected to leverage their previous SBIR support, as well as the opportunity to compete for additional funding through the NHLBI Bridge Award program, to attract and negotiate third-party financing needed to advance a product or technology toward commercialization. The applicant’s ability to secure independent third-party investor funds that equal or exceed the total amount of the NHLBI funds being requested over the entire Bridge Award project period will help to validate the commercial potential that is essential for the SBIR projects solicited under the Bridge Award program. It is anticipated that many of the partnerships between small businesses and third-party investors will involve a considerable level of project due diligence by the private sector, thereby increasing the likelihood of commercial success for the funded projects. In light of these goals, the NHLBI strongly encourages applicants to establish business relationships with investors, strategic partners or both that have appropriate prior experience in commercializing emerging biomedical technologies.
back to top
Holding the keys to the future of health care and medicine is not something many children dream of doing.
But Bahija Jallal, executive vice president of AstraZeneca’s (AZN) biologics arm, MedImmune, knew from a very young age that was the career she was destined for.
back to top
The University of Maryland has signed an agreement for a student-exchange program with the University of Jordan that will boost research and the flow of students between College Park and the Middle East country’s largest and oldest university.
The announcement of the pact by University of Maryland President Wallace D. Loh comes as a delegation led by Gov. Martin O’Malley visits Jordan on the first leg of an eight-day trip to Jordan and Israel.
back to top
A doctor might ask for a patient's family disease history, or exercise or smoking habits, but whether they have trouble getting food onto the table or paying energy bills is unlikely to appear on any clinic questionnaire.
Those sorts of factors could have just as much, if not more, of an impact on a person's everyday health, argue the founders of a startup out of the Johns Hopkins University. Their company, Healthify, is giving clinics that serve largely low-income populations the means to gather and use that information.
back to top
The Biotechnology Industry Organization (BIO) today issued the annual Scientific American Worldview Report and Bio-Innovation Scorecard. On Wednesday, April 24, the Scientific American Worldview Super Session will take place during the 2013 BIO International Convention, the global biotechnology event, in Chicago, Ill. at McCormick Place.
Moderated by Fareed Zakaria, author, journalist and host of CNN's Fareed Zakaria GPS, the Convention Super Session is the marquee discussion forum among industry leaders on the state of biotech hubs and innovation around the globe. Panelists include Trevor Mundel, President, Global Health Program for The Bill & Melinda Gates Foundation; Robert Hariri, Chief Executive Officer, Celgene Cellular Therapeutics; Tomas Philipson, Daniel Levin Professor of Public Policy, The University of Chicago; and Sam Pitroda, Chairman, National Innovation Council, Government of India. The session will be held from 3:45pm to 5:15pm.
back to top
May 7, 2013, 8:00am – 5:30pm (EDT)
NCI Shady Grove, 9609 Medical Center Drive, Rockville, MD 20850
This workshop will include opportunities for one-on-one meetings with representatives of many of the presenting federal organizations. Please indicate your interest and top three choices below for one-on-one meetings. NCI SBIR Program Directors will also be available to meet on the afternoon of May 6. If you are interested in setting up a meeting on May 6, please mark the appropriate selection on the registration form below.
On May 6 at 6pm (EDT), NCI SBIR will host an informal, optional meet and greet at the Cafe Deluxe in the Rio Entertainment Center (9811 Washingtonian Boulevard Gaithersburg, MD 20878 – Terrace Room). Due to government restrictions, the meet and greet will be self-pay. Please RSVP below, as space for the meet and greet is limited.
Due to space limitations, priority will be given to current or recent NCI SBIR or STTR awardees, with a maximum of two (2) representatives allowed per company. This workshop is provided free of charge to attendees (excluding food and transportation expenses).
back to top
A Columbia University administrator is taking over a top post at Johns Hopkins University.
Robert C. Lieberman will take on the role of provost and senior vice president for academic affairs at Hopkins July 1. Lieberman is currently the interim dean of Columbia’s School of International and Public Affairs.
back to top
Once again we’re stepping into spring with more exciting programming in health entrepreneurship. Our Rock Health Skillshare series is open to the public and provides a unique opportunity to get an in-depth look at critical issues in health innovation, as well as a peek at Rock Health HQ in Chinatown (Dim sum anyone?). Classes generally range from $25-$30 and we provide snacks, refreshments, and ample opportunity for networking afterward. Our teachers have extensive real-world domain expertise that they are enthusiastic about sharing with others.
back to top
The Association of University Research Parks is proud to present the 18th Annual Awards of Excellence in research and science park development and practice. AURP will honor industry leaders at the 2013 International Conference in Philadelphia, Pennsylvania.
These awards bring valuable recognition to the recipients and to the industry as a whole. To nominate a park, company or an individual who has demonstrated excellence in the field, please use the below links. Each link also provides criteria and details about the award. Nominations are due by May 20, 2013.
back to top
Today, the National Venture Capital Association (NVCA) and the Medical Innovation and Competitiveness Coalition (MedIC) released Patient Capital 3.0: Confronting the Crisis and Achieving the Promise of Venture-Backed Medical Innovation. The report, which is in its third release, highlights the contribution of venture capital to medical innovation and provides perspective on the current investment environment in the U.S. for life sciences.
“Venture-backed medical innovations still provide the critical new drugs, medical devices and diagnostics that improve and save the lives of millions of Americans, but the environment for investing in these breakthroughs has become increasingly challenging,” said Jonathan Leff, Partner at Deerfield Management and Chairman of MedIC. “While the promise of science to help solve our most pressing medical problems is extraordinary, the time, cost and uncertainty involved in building start-up companies that advance fundamental medical innovations have all risen, driving some investors away from the life sciences arena in recent years. We continue to express to policymakers the importance of promoting an environment that encourages investment in medical innovation.”
back to top
Google Ventures has been backing startups through its venture capital fund since 2009 and offers a pretty diverse range of services to entrepreneurs. Here’s a look at the eight healthcare and life science businesses among its portfolio companies spanning DNA analysis, accelerated drug development, and oncology analytics.
23andMe The startup has helped make personal genetics and DNA analysis much more accessible to consumers. The company, co-founded by Anne Wojsicki, offers DNA test kits that for $99 and a little saliva help people better understand what conditions they are at risk for developing, whether they are carriers for any diseases that they could unwittingly give to their children. It can also provide information on whether people’s genetic makeup makes them particularly sensitive to certain drugs. It also uses results from user queries, with their consent, to conduct in-house research.
back to top
|
